Pacira BioSciences Q2 earnings call highlights. August 4, 2026 Key points. * Second-quarter revenue rose 6% to $192.4 million, driven by EXPAREL, ZILRETTA and iovera° sales; adjusted EBITDA was approximately $48.7 million. * EXPAREL continued gaining share despite weakness in elective soft-tissue procedures, supported by growth in outpatient settings and expanded UnitedHealthcare coverage that brought separate reimbursement to more than 150 million covered lives. * Pacira completed the sale of iovera° to Zimmer Biomet and expects up to $140 million in proceeds, while lowering full-year revenue guidance to $735 million-$760 million; three key clinical readouts are expected by year-end. * MarketBeat previews top five stocks to own in September. Pacira BioSciences NASDAQ: PCRX reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet. Total second-quarter revenue rose 6% from the prior-year period to $192.4 million, according to Chief Financial Officer Shawn Cross. The company reported GAAP net income of $4.7 million, or $0.12 per diluted share, and adjusted EBITDA of approximately $48.7 million. EXPAREL net product sales increased 3% to $147.8 million, while volume grew approximately 4%. Cross said the difference between volume and revenue growth reflected vial mix and discounting associated with the company's third group purchasing organization, which began operating in mid-2025. Pacira expects that gap to narrow as it laps the prior-year impact. EXPAREL gains share despite elective-procedure softness. Chief Executive Officer Frank Lee said EXPAREL continued to gain penetration across market segments even as macroeconomic pressure affected certain elective soft-tissue procedures, particularly in hospital inpatient settings. The company said EXPAREL volumes are approximately 60% orthopedic and 40% soft tissue. Chief Commercial Officer Brendan Teehan said orthopedic procedures remained relatively stable during the quarter, while elective soft-tissue procedures slowed, with the declines more pronounced in inpatient hospitals. He attributed the trend in part to softer consumer healthcare spending and broader economic uncertainty affecting deferrable procedures. Pacira said it is concentrating on ambulatory surgery centers, hospital outpatient settings and procedures it considers more resilient to macroeconomic conditions. Teehan said EXPAREL significantly outpaced the broader market in ambulatory surgery centers, where procedure volumes were modestly higher overall. The company also cited progress on reimbursement. UnitedHealthcare expanded EXPAREL coverage to provide separate reimbursement outside the surgical bundle, adding approximately 40 million covered lives. Pacira said EXPAREL now has separate reimbursement for more than 150 million covered lives, or roughly half of medically insured lives in the United States, and remains on track toward its year-end target of 160 million. During the question-and-answer session, Lee said Pacira's outlook does not assume a broad recovery in elective procedures. Instead, the company expects growth from outpatient settings, commercially reimbursed procedures, payer wins and continued share gains. ZILRETTA, iovera° and Partnership Developments. ZILRETTA sales rose 4% to $32.6 million in the quarter. Teehan said growth reflected commercial investments made last year, including a dedicated ZILRETTA sales force and the company's partnership with Johnson & Johnson. UnitedHealthcare also placed ZILRETTA on its preferred drug list, eliminating prior authorization requirements, according to Pacira. Discover more Market Cap Calculator Financial News Subscription iovera° sales grew 21% to $6.8 million. Pacira completed the divestiture of the product to Zimmer Biomet on July 31. Under the transaction, Pacira is eligible to receive up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones. Lee said the transaction sharpens Pacira's focus on becoming an innovation-driven biopharmaceutical company and allows it to direct capital toward higher-return opportunities. Pacira will continue collaborating with Zimmer Biomet on the iovera° spasticity program, with potential additional compensation tied to clinical and regulatory success. The company also said LG Chem recently submitted a regulatory filing for EXPAREL in South Korea. Pacira expects revenue from that arrangement to begin in 2027 and plans to provide updates on additional international commercial partnerships during the second half of the year. Pipeline readouts expected by year-end. Pacira said it expects three top-line clinical readouts by year-end: a registrational study of iovera° in spasticity, a Phase III study of ZILRETTA in shoulder osteoarthritis, and Part A of the Phase II ASCEND study for PCRX-201 in knee osteoarthritis. Enrollment has been completed in the iovera° spasticity registrational study, while enrollment has opened for Part B of the PCRX-201 Phase II trial. Part A randomized 49 patients to two PCRX-201 dose groups or a saline control. All participants received an intra-articular corticosteroid before treatment, with safety as the primary objective and efficacy endpoints assessed at weeks 38 and 52. Chief Medical Officer Jonathan Slonin said the Part A data are expected at the end of the year and are designed to provide safety insights and assess efficacy trends. Pacira expects to report additional data sets during 2027. The company also said it has established a U.S.-based commercial manufacturing process for PCRX-201 and has begun a pilot efficacy study in canine osteoarthritis. In addition, Pacira plans to begin Phase II development later this year for PCRX-2002, a hydrogel formulation of ropivacaine intended to provide rapid-onset and long-acting postsurgical analgesia from a single instillation into the surgical field. Guidance updated following iovera° sale. Pacira lowered its full-year total revenue guidance to $735 million to $760 million from a previous range of $745 million to $770 million, reflecting the iovera° divestiture. The company maintained its EXPAREL net product sales outlook of $600 million to $620 million. The company reduced its full-year SG&A guidance to $310 million to $330 million, from $320 million to $340 million, and narrowed stock-based compensation guidance to $54 million to $59 million. Pacira reiterated guidance for non-GAAP gross margin of 77% to 79% and non-GAAP research and development expense of $105 million to $115 million. Pacira ended the quarter with $251 million in cash and investments, before the $70 million upfront payment from the Zimmer Biomet transaction. Cross said the company expects the fourth quarter to be its largest dollar contributor for EXPAREL sales, following historical seasonal patterns. About Pacira BioSciences (NASDAQ:PCRX). Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain. In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Pacira BioSciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list. While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Zimmer Biomet has agreed to acquire Pacira BioSciences' iovera pain relief device for up to $140 million, comprising $70 million upfront and up to $70 million in revenue-based milestones through 2031. Iovera uses extreme cold to disrupt pain signals in targeted nerves, treating conditions including knee pain from osteoarthritis or surgery, as well as hip, shoulder, foot and spine pain. The device generated $24.2 million in sales last year, growing 6%. BTIG analyst Ryan Zimmerman noted the acquisition complements Zimmer's orthopaedics portfolio and benefits from legislation expanding access to non-opioid pain treatments. Zimmer will collaborate on Pacira's ongoing spasticity trial, with Pacira eligible for additional compensation upon successful completion and regulatory approval. The deal is expected to close in the third quarter.

Pacira BioSciences joins Life Science Cares as National Corporate Partner. News | June 29, 2026 Pacira BioSciences joins Life Science Cares as National Corporate Partner to fight poverty in key biotech hubs. Collaboration expands community impact across the San Francisco Bay Area, San Diego, and New Jersey. SAN FRANCISCO, June 29, 2026, Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined Life Science Cares (LSC) as a National Corporate Partner. Through this multi-region partnership, Pacira will provide financial support and employee volunteer engagement to help address poverty and inequality across three major life science hubs: the San Francisco Bay Area, San Diego, and New York/New Jersey. By aligning with Life Science Cares, Pacira joins a collective effort within the life sciences sector to support high-impact nonprofits providing access to basic needs, education, and economic opportunity. "At Pacira, we believe that true leadership in healthcare extends far beyond the treatments we develop; it requires a deep commitment to the health and well-being of the communities we serve," said Kristen Williams, Chief Administrative Officer & Secretary at Pacira BioSciences. "Joining Life Science Cares as a national partner allows our team to turn our passion into purpose, actively breaking down systemic barriers and building brighter, more sustainable futures alongside our industry peers." "Partnerships like this are the heart of our mission," said Sarah MacDonald, Life Science Cares CEO. "We are excited to partner with Pacira and showcase how mobilizing resources and people power for those who need it most can have a tremendous impact. Together, we are proving that the life sciences industry can play a powerful role in breaking the cycle of poverty and creating real, lasting change." The collaboration between Pacira and Life Science Cares showcases how corporate social responsibility and employee engagement can drive local impact. Beyond corporate funding, Pacira employees will engage in hands-on volunteerism designed to bridge the opportunity gap for underrepresented populations. Life Science Cares impact at a glance. Over the last decade, thanks to partnerships with forward-thinking companies like Pacira, Life Science Cares has built a robust legacy of systemic support: * Invested over $26M in high-impact nonprofits * Engaged over 31K+ volunteers from across the industry * Dedicated nearly 80K+ hours to volunteering * Placed more than 1,300+ low-income undergraduate students in paid summer internships in the industry across 345 companies About Pacira Biosciences Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL(R)(bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA(R)(triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera(R) °, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com. About Life Science Cares Life Science Cares (LSC) activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in its communities. Now operating in five US life science hubs (Boston, Philadelphia, San Diego, the San Francisco Bay Area, and New York) as well as Switzerland, LSC has invested $26 million and engaged over 30,000 volunteers in the industry in community organizations providing access to basic needs, access to education, or access to opportunity. To learn more about Life Science Cares, visit https://lifesciencecares.org/.